Compare ITGR & PBLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ITGR | PBLS |
|---|---|---|
| Founded | 1970 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 3.6B |
| IPO Year | 2000 | 2026 |
| Metric | ITGR | PBLS |
|---|---|---|
| Price | $126.44 | $29.99 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | ★ $121.80 | $41.75 |
| AVG Volume (30 Days) | ★ 704.2K | 679.6K |
| Earning Date | 10-22-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.17 | N/A |
| Revenue | ★ $1,853,637,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.96 | $222.58 |
| P/E Ratio | $108.03 | ★ N/A |
| Revenue Growth | ★ 7.98 | N/A |
| 52 Week Low | $62.00 | $25.56 |
| 52 Week High | $126.80 | $42.49 |
| Indicator | ITGR | PBLS |
|---|---|---|
| Relative Strength Index (RSI) | 73.58 | 39.57 |
| Support Level | $126.16 | $26.42 |
| Resistance Level | $126.54 | $33.65 |
| Average True Range (ATR) | 0.18 | 3.16 |
| MACD | -0.44 | -0.72 |
| Stochastic Oscillator | 63.64 | 20.05 |
Integer Holdings Corp is a manufacturer of medical device components used by original equipment manufacturers in the medical industry. The firm organizes itself into one segment and derives its revenues from three product lines: Cardio & Vascular, Cardiac Rhythm Management & Neuromodulation and Other Markets. The company earns maximum of its revenue in the United States, and also has its presence in Ireland, Puerto Rico, Costa Rica, and Rest of the World.
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.